丁甲基与伊德本结合对血管痴呆症的影响:一项追溯观察分析
Hongxia Zhang1, Huijun Wu, Xiaoyuan Qi
1Department of Neurology, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Medicine
|March 1, 2024
概括
丁甲基与伊德诺结合,通过改善认知功能和日常生活能力,有效治疗血管痴呆症. 这种组合可以安全地减少炎症和氧化应激,显示出比单独使用丁甲胺更好的结果.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 血管痴呆症 (VaD) 是认知障碍的一个重要原因.
- 目前用于VaD的治疗方法在有效性和安全性方面存在局限性.
- 炎症和氧化应激是VaD的关键病理机制.
研究的目的:
- 评估结合丁甲酸与伊德本治疗血管痴呆症的有效性和安全性.
- 为了比较组合疗法与单独布甲胺对VAD患者认知功能,炎症标志物和氧化应激的影响.
主要方法:
- 来自126名VaD患者的临床数据的回顾性审查.
- 患者被分为两组:单独使用丁甲基 (62) 和结合丁甲基与idebenone (64).
- 在治疗前后评估认知功能,血清炎症因子,氧化应激指数和不良反应.
主要成果:
- 组合组在认知功能得分 (哈塞加瓦痴呆症量表,迷你精神状态检查) 和日常生活活动方面表现得明显更好,相比单独服用丁甲酸的组.
- 用丁甲酸和伊德本治疗显著降低了血清中C反应性蛋白,瘤亡因子α和6.
- 组合疗法导致血清葡萄糖过氧化酶和超氧化脱氧化酶的水平提高,并降低了甲基的水平,表明氧化应激减少.
- 两组之间在不良反应发生率上没有发现显著差异.
结论:
- 丁甲基与伊德本结合,是血管痴呆症的安全有效治疗方法.
- 组合疗法显著改善了VaD患者的认知功能和日常生活活动.
- 这种治疗策略有效地减轻了与血管痴呆病原发生有关的炎症和氧化应激途径.
相关概念视频
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268


